Biosimilar and Interchangeable Products: What Do Pharmacists Need to Know?

July 29, 2021 | 1-2 PM

This webinar will provide an overview of the scientific concepts for biological products and the scientific and regulatory basis for the biosimilar pathway. Presenters from Food and Drug Administration (FDA) will discuss updates about important and timely issues related to biosimilar and interchangeable products for pharmacists. In addition, the presenters will

1. Review practical information regarding the use of these products, such as labeling and pharmacy substitution.

2. Demonstrate the functionality of the enhanced Purple Book resource that is available to health care professionals.

3. Provide resources to help pharmacists educate patients about biosimilar and interchangeable products.

CPE Credit

The complimentary webinar is eligible for Accreditation Council for Pharmacy Education (ACPE)-accredited continuing pharmacy education (CPE) credit. More details regarding the presentations, CPE activity credits, and browser requirements can be found in the CPE Activity Information Guide.

Presenters

Sarah Yim, MD

Director of the Office of Therapeutic Biologics and Biosimilars, Food and Drug Administration

Sarah Yim, MD, is the Director of the Office of Therapeutic Biologics and Biosimilars, in CDER’s Office of New Drugs (OND), Food and Drug Administration (FDA)FDA.  Prior to that, she spent two years as Director of the Division of Clinical Review in the Office of Generic Drugs, and 11 years in various roles in rheumatology drug review in OND.  She received her undergraduate degree from Stanford University, her Doctor of Medicine degree from the Uniformed Services University of Health Sciences, and completed a postdoctoral fellowship in rheumatology at the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), at the National Institutes of Health

Sarah Ikenberry, MA

Senior Communication Advisor for the Office of Therapeutic Biologics and Biosimilars, Food and Drug Administration

Sarah Ikenberry, MA, is a Senior Communication Advisor for the Office of Therapeutic Biologics and Biosimilars (OTBB) in FDA’s Center for Evaluation and Research (CDER) where she provides communication advice and support to senior leaders and the agency about communicating strategic priorities, initiatives and educational information about biosimilar and interchangeable products. Sarah has a Master of Arts in Communication from Johns Hopkins University.